Avinger Reports Fourth Quarter 2022 Results
Avinger, Inc. (NASDAQ:AVGR) reported its fourth quarter and full-year results for 2022, highlighting a revenue of $2.0 million and a gross margin of 34%. The revenue decreased from $2.4 million in Q4 2021 primarily due to a reduced sales headcount. The company has filed an FDA 510(k) submission for the new Pantheris LV device and is preparing for additional product launches in 2023. Operating expenses decreased by 15% year-over-year, amounting to $4.5 million. The net loss for Q4 2022 was $4.2 million, slightly improved from $5.0 million in Q4 2021. As of December 31, 2022, cash and equivalents stood at $14.6 million.
- Successfully filed FDA 510(k) submission for Pantheris LV device, enhancing product offerings.
- Gross margin improved to 34% from 30% year-over-year due to favorable product mix.
- Operating expenses decreased by 15% year-over-year, reflecting cost efficiencies.
- Strong cash position of $14.6 million supports ongoing operations and product development.
- Fourth quarter revenue declined to $2.0 million from $2.4 million in Q4 2021, primarily due to reduced sales headcount.
- Net loss of $4.2 million remains a concern, despite improvements from previous quarters.
REDWOOD CITY, CA / ACCESSWIRE / March 15, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the fourth quarter and full year ended December 31, 2022.
Fourth Quarter and Recent Highlights
- Fourth quarter revenue of
$2.0 million , and gross margin of34% - Filed an FDA 510(k) submission for the new Pantheris LV (large vessel) device which brings important new features and benefits to Avinger's Pantheris family of image-guided atherectomy catheters
- Expanded penetration of Lightbox 3 next-generation imaging console with approximately 600 cases performed in more than 60 clinical sites since launch
- Advanced development program for first ever image-guided coronary CTO-crossing system and evaluated prototypes with expanded coronary clinical advisory board
- Continued enrollment in the Pantheris SV IMAGE-BTK clinical study (small vessel, below-the-knee), which continues to generate outstanding clinical outcomes data in a challenging patient population
- Maintained a strong cash position of
$14.6 million at December 31, 2022
"We reported solid operating metrics in the fourth quarter, improving gross margin from the prior year on favorable product mix and driving efficiencies in our operating cost model as we advanced multiple product and clinical programs to position the company for future growth," commented Jeff Soinski, Avinger's President and CEO.
"Our recent 510(k) filings provide the opportunity for two new peripheral product launches in 2023. We have submitted all requested documentation related to the 510(k) submission for our new Tigereye ST CTO-crossing catheter and are preparing to initiate limited launch pending FDA clearance. In January, we filed a 510(k) submission for Pantheris LV, which streamlines the atherectomy procedure and expands our capabilities for the treatment of large vessel disease. We hope to receive FDA clearance for this new device by mid-year to allow for commercial launch in the second half of this year.
"We are excited about the progress we are making in the development of our first coronary product application. Crossing chronic total occlusions in the coronary arteries is a complex, expensive and uncertain procedure utilizing currently available technology. By leveraging our proprietary OCT-guided platform, we believe we can revolutionize this market with the first and only image-guided system for crossing coronary CTOs. Over the past several months, we have evaluated different design approaches in bench top models and have recently gained important feedback from our clinical advisory board for further design iteration. We expect to assess these prototypes in animal studies in the second quarter of this year as we work towards our goal of filing an IDE submission with the FDA within the next 12 months to allow for initiation of a clinical study in 2024."
Fourth Quarter 2022 Financial Results
Total revenue was
Gross margin for the fourth quarter of 2022 was
Net loss and comprehensive loss for the fourth quarter of 2022 was
Adjusted EBITDA, as defined under non-GAAP financial measures in this press release, was a loss of
Cash and cash equivalents totaled
Conference Call
Avinger will hold a conference call today, March 15, 2023, at 4:30pm ET to discuss its fourth quarter and year end 2022 financial results.
To listen to a live webcast, please visit http://www.avinger.com and select Investor Relations. To join the call by telephone, please dial +1-973-528-0011 and use passcode 514070. A webcast replay of the call will be available on Avinger's website following completion of the call at www.avinger.com.
About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot and Tigereye® family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.
Follow Avinger on Twitter and Facebook.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our future performance, patient and physician benefits of our products , the impacts of our products on the treatment of vascular disease, our ability to successfully develop new products, including products relating to the treatment of coronary artery disease (CAD), the timing of the development of new products, the impact of products developed for the treatment of CAD on our business and results of operations, the potential success of our coronary product application, the receipt of FDA clearance of our 510(k) applications for our new Tigereye ST CTO-crossing catheter and new Pantheris LV atherectomy catheter, and our expectation regarding assessing coronary prototypes in animal studies and the timing relating to our goal of filing an IDE submission relating to a clinical study. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include our dependency on a limited number of products; the resource requirements related to Pantheris, Tigereye and our Lightbox imaging console; the outcome of clinical trial results; the adoption of our products by physicians; our ability to obtain regulatory approvals for our products; as well as the other risks described in the section entitled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 22, 2022 and Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Avinger disclaims any obligation to update these forward- looking statements.
Non-GAAP Financial Measures
Avinger has provided in this press release financial information that has not been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The Company uses these non-GAAP financial measures internally in analyzing its financial results and believes that the use of these non-GAAP financial measures is useful to investors as an additional tool to evaluate ongoing operating results and trends and in comparing the Company's financial results with other companies in its industry, many of which present similar non-GAAP financial measures.
The presentation of these non-GAAP financial measures should not be considered in isolation or as a substitute for comparable GAAP financial measures, and should be read only in conjunction with the Company's financial statements prepared in accordance with GAAP. A reconciliation of the Company's non-GAAP financial measures to their most directly comparable GAAP measures has been provided in the financial statement tables included in this press release, and investors are encouraged to review these reconciliations.
Adjusted EBITDA. Avinger defines Adjusted EBITDA as net loss and comprehensive loss plus interest expense, net, plus other income, net, plus stock-based compensation expense plus certain inventory charges plus certain depreciation and amortization expense. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools. Furthermore, these non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP, and the components that Avinger excludes in its calculation of non-GAAP financial measures may differ from the components that its peer companies exclude when they report their non-GAAP results of operations. Avinger compensates for these limitations by providing specific information regarding the GAAP amounts excluded from these non-GAAP financial measures. In the future, the Company may also exclude other non-recurring expenses and other expenses that do not reflect the Company's core business operating results.
Investor Contact:
Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com
Public Relations Contact:
Phil Preuss
Chief Marketing Officer
Avinger, Inc.
(650) 241-7942
pr@avinger.com
Statements of Operations and Comprehensive Loss
(in thousands, except per share amounts) (unaudited)
| For the Three Months Ended | Twelve Months Ended | |||||||||||||||||||
| December 31, | September 30, | December 31, | December 31, | December 31, | ||||||||||||||||
| 2022 | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||
Revenues | $ | 2,001 | $ | 2,252 | $ | 2,403 | $ | 8,273 | $ | 10,130 | ||||||||||
Cost of revenues | 1,318 | 1,462 | 1,691 | 5,619 | 6,706 | |||||||||||||||
Gross profit | 683 | 790 | 712 | 2,654 | 3,424 | |||||||||||||||
Operating expenses | ||||||||||||||||||||
Research and development | 1,146 | 1,086 | 1,398 | 4,390 | 5,900 | |||||||||||||||
Selling, general and administrative | 3,359 | 3,384 | 3,870 | 14,221 | 15,625 | |||||||||||||||
Total operating expenses | 4,505 | 4,470 | 5,268 | 18,611 | 21,525 | |||||||||||||||
Loss from operations | (3,822 | ) | (3,680 | ) | (4,556 | ) | (15,957 | ) | (18,101 | ) | ||||||||||
Interest expense, net | (379 | ) | (407 | ) | (434 | ) | (1,665 | ) | (1,648 | ) | ||||||||||
Other income (expense), net | 19 | - | (6 | ) | (1 | ) | 2,337 | |||||||||||||
Net loss and comprehensive loss | (4,182 | ) | (4,087 | ) | (4,996 | ) | (17,623 | ) | (17,412 | ) | ||||||||||
Accretion of preferred stock dividends | (1,129 | ) | (1,127 | ) | (1,043 | ) | (4,510 | ) | (4,175 | ) | ||||||||||
Deemed dividend arising from beneficial conversion feature of convertible preferred stock | - | - | - | (5,111 | ) | - | ||||||||||||||
Net loss applicable to common stockholders | $ | (5,311 | ) | $ | (5,214 | ) | $ | (6,039 | ) | $ | (27,244 | ) | $ | (21,587 | ) | |||||
Net loss per share attributable to common stockholders | ||||||||||||||||||||
basic and diluted | $ | (0.70 | ) | $ | (0.77 | ) | $ | (1.26 | ) | $ | (4.36 | ) | $ | (4.57 | ) | |||||
Weighted average common shares used to compute | ||||||||||||||||||||
net loss per share, basic and diluted | 7,569 | 6,798 | 4,778 | 6,249 | 4,722 | |||||||||||||||
| All share and per share data reflect the impact of the 1-for-20 reverse stock split of the Company's issued and outstanding common stock that became effective on March 14, 2022. | ||||||||||||||||||||
Reconciliation of Adjusted EBITDA to Net loss and comprehensive loss
(in thousands) (unaudited)
| For the Three Months Ended | Twelve Months Ended | |||||||||||||||||||
| December 31, | September 30, | December 31, | December 31, | December 31, | ||||||||||||||||
| 2022 | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||
Net loss and comprehensive loss | $ | (4,182 | ) | $ | (4,087 | ) | $ | (4,996 | ) | $ | (17,623 | ) | $ | (17,412 | ) | |||||
Add: Interest expense, net | 379 | 407 | 434 | 1,665 | 1,648 | |||||||||||||||
Add: Other income (expense), net | (19 | ) | - | 6 | 1 | (2,337 | ) | |||||||||||||
Add: Stock-based compensation | 1 | 39 | 55 | 127 | 1,015 | |||||||||||||||
Add: Certain depreciation and amortization charges | 63 | 54 | 162 | 196 | 687 | |||||||||||||||
Adjusted EBITDA | $ | (3,758 | ) | $ | (3,587 | ) | $ | (4,339 | ) | $ | (15,634 | ) | $ | (16,399 | ) | |||||
Balance Sheets
(in thousands, except per share amounts) (unaudited)
| December 31, | December 31, | |||||||
Assets | 2022 | 2021 | ||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 14,603 | $ | 19,497 | ||||
Accounts receivable, net of allowance for doubtful accounts | ||||||||
of | 1,057 | 1,393 | ||||||
Inventories | 4,965 | 4,601 | ||||||
Prepaid expenses and other current assets | 362 | 300 | ||||||
Total current assets | 20,987 | 25,791 | ||||||
Right of use asset | 2,194 | 3,179 | ||||||
Property and equipment, net | 702 | 95 | ||||||
Other assets | 312 | 420 | ||||||
Total assets | $ | 24,195 | $ | 29,485 | ||||
Liabilities and stockholders' equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 631 | $ | 1,394 | ||||
Accrued compensation | 1,401 | 1,609 | ||||||
Accrued expenses and other current liabilities | 657 | 718 | ||||||
Leasehold liability, current portion | 1,092 | 985 | ||||||
Borrowings, current portion | 14,165 | - | ||||||
Total current liabilities | 17,946 | 4,706 | ||||||
Borrowings, current portion | - | 12,287 | ||||||
Leasehold liability, long-term portion | 1,102 | 2,194 | ||||||
Other long-term liabilities | 1,001 | 575 | ||||||
Total liabilities | 20,049 | 19,762 | ||||||
Stockholders' equity: | ||||||||
Convertible preferred stock, par value | - | - | ||||||
Common stock, par value | 8 | 5 | ||||||
Additional paid-in capital | 406,514 | 394,471 | ||||||
Accumulated deficit | (402,376 | ) | (384,753 | ) | ||||
Total stockholders' equity | 4,146 | 9,723 | ||||||
Total liabilities and stockholders' equity | $ | 24,195 | $ | 29,485 | ||||
SOURCE: Avinger, Inc.
View source version on accesswire.com:
https://www.accesswire.com/743839/Avinger-Reports-Fourth-Quarter-2022-Results
FAQ
What were Avinger’s revenue and gross margin for Q4 2022?
When did Avinger file for FDA 510(k) approval for the Pantheris LV device?
What was Avinger’s net loss for the fourth quarter of 2022?
How much cash did Avinger have at the end of 2022?
What are the key highlights from Avinger's Q4 2022 financial results?
